The top U.S. infectious disease official says concerns over leaks compelled him to reveal data on Gilead Sciences Inc.'s experimental drug remdesivir, the first in a scientifically rigorous clinical trial to show benefit in treating COVID-19.
The top U.S. infectious disease official says concerns over leaks compelled him to reveal data on Gilead Sciences Inc.'s experimental drug remdesivir, the first in a scientifically rigorous clinical trial to show benefit in treating COVID-19.
Post a Comment
EmoticonClick to see the code!
To insert emoticon you must added at least one space before the code.